newsfilter
← Latest News
GlobeNewswire·

XORTX Patent Allowed for XRx-101 Program by Japan Patent Office

XRTX
  • XORTX Therapeutics Inc. announced that the Japan Patent Office issued a Decision to Grant a patent for its Japanese Patent Application No. 2022-556140 covering compositions, formulations, & containers.
  • The patent application is the Japanese national phase of International Application No. PCT/IB2021/000238 & claims priority to U.S. Provisional Application No. 62/989,879 filed on March 15, 2020.
  • Once registered upon payment of the registration fee, the patent will protect XORTX's XRx-101 program for acute kidney injury & other acute organ injury linked to respiratory virus infections.
  • The six allowed claims cover pharmaceutical compositions comprising xanthine oxidase inhibitors, including oxypurinol, for treating or preventing acute kidney injury & health consequences associated with viral infections.
  • Upon registration, the Japanese Patent is expected to remain in force until March 15, 2041, subject to annuity fees & excluding potential patent term extensions.
  • This represents XORTX's first patent in Japan directed to its xanthine oxidase inhibitor programs, strengthening the intellectual property position for both XRx-101 & XORLO™ for gout.
  • XORTX's portfolio now includes seven granted or allowed patents & 14 pending applications in the U.S., Europe, & Japan, alongside approximately 30 patents from the acquired VB4-P5 renal anti-fibrotic program.
  • The Company has not entered into any partnering or licensing agreements for XRx-101 & provides no assurance that such agreements will be reached.
  • XORTX is advancing three clinically advanced programs: XRx-026 for gout, XRx-008 for ADPKD, & XRx-101 for acute kidney injury associated with respiratory viruses.
  • The press release contains forward-looking statements regarding patent issuance, term, protection scope, & potential partnering, which are subject to risks including challenges to patent validity or failure to obtain regulatory approval.
Company
XORTX Therapeutics Inc.
Keywords
TSX Venture Exchange:XRTX, XORTX Therapeutics Inc.